Article

Submission pathways explored in ARCS Regulatory Summit

Updated date October 13, 2026
Learn what TGA speakers at the first ARCS Regulatory Summit said about priority designation, provisional registration and upcoming TGA medicine reforms.
The first ARCS Regulatory Summit, held in February 2025,3 brought together speakers from the Therapeutic Goods Administration (TGA) to provide practical regulatory insights on a range of topics. The interactive, workshop-style event, which was held in Canberra, explored TGA collaboration and expedited regulatory pathways (including priority designations and provisional registration pathways), evaluation issues and common deficiencies, post-approval change management (ICH Q12), labeling updates, and other anticipated reforms. 

One of the key topics covered was priority designation, which provides faster assessment of vital and life-saving prescription medicines with a target timeframe of 150 working days (compared with 255 working days for the standard registration pathway).1 

The priority review follows a designation process where approximately 8 to 10 applications are granted priority designation per year. The TGA presenter emphasized that the decision to determine whether a medicine should be granted priority designation was based on the strength of evidence provided by the sponsor in addressing eligibility criteria.

Demonstration of an improvement in efficacy and/or safety compared to registered medicines and the justification of major therapeutic advance were considered most significant. The presenter pointed out that priority designations were not granted or rejected based on TGA workload and reiterated that rejection of priority designation is simply that the medicine is not eligible for the shorter assessment timeframe. If priority designation is not granted, sponsors can still apply to register their medicine under the standard registration pathway. 

A second topic covered was the provisional registration pathway.2 This is a mechanism where medicines are registered on the basis of preliminary clinical data and where the benefit of early availability of the medicine outweighs potential risk. The availability of comprehensive non-clinical data on safety, quality and compliance with Good Manufacturing Practice is expected. Acceptance for evaluation via the provisional pathway involves a designation process where defined eligibility criteria need to be met, including a clear timeline for the provision of additional clinical data for conversion to a full registration. While granting a provisional determination is a prerequisite of the provisional pathway, the TGA reminded the audience that provisional registration or approval of the medicine is not guaranteed. 

Finally, the TGA brought attention to planned reforms to the prescription medicine process aimed at achieving greater consistency and improved decision predictability, as well as enhancing stakeholder experience and engagement. The reforms also seek to optimize resources and capabilities to improve access to medicines by reducing registration times. These reforms will be increasingly important as the volume of submissions increases and with it a continued backlog. With advances in automation and artificial intelligence in research and development expected to continue, the TGA is looking to adapt its processes to these changes. 

Although the reforms are still in the early phase, further progress is anticipated. As of June 11, 2026, the TGA described its reform program as ongoing, with AI tools and automation expected to be delivered in the second half of 2027.4

Disclaimer:
The information in this article is intended to inform readers about a topic related to Cencora's capabilities and is not legal or purchasing advice. Cencora, Inc. encourages readers to review the cited references in this article and use their own knowledge and experience when making decisions.
 

 

We're here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.
abstract

Related solutions

New marketing authorization applications
Navigate NDA, BLA, and MAA submissions with cross-functional regulatory support and an independent readiness assessment before filing a new application.
  • Commercialization support
  • Pharma
  • Global
Health authority interactions
We help life sciences teams navigate health authority interactions across development, review, and post-approval with clear strategy and actionable guidance.
  • Commercialization support
  • Pharma
  • Global
Regulatory writing
Turn complex scientific, clinical, and quality data into clear, accurate, submission-ready documents across development and lifecycle management.
  • Commercialization support
  • Pharma
  • Global

Related resources

meeting

Article

Thinking like a regulator: How to reduce risk in the first-cycle submission review
Associate reading their laptop screen in an office

Webinar

Thinking like a regulator: De-risking first-cycle submission review

Article

Exploring alternative submission pathways

References 
1. Therapeutic Goods Administration. "Applying for a Prescription Medicine via the Priority Review Pathway." May 2025.
2. Therapeutic Goods Administration. "Applying for a Prescription Medicine via the Provisional Registration Pathway." May 2025.
3. Therapeutic Goods Administration. "TGA Presentations: ARCS 2025 Regulatory Summit." February 2025.
4. Therapeutic Goods Administration. "Prescription Medicine Authorisation Branch Update: Q&A Panel Session." ARCS Annual Conference 2026, June 11, 2026.